Kamuvudine-9 for diabetic macular edema
Part of Eyes & vision clinical trials.
This trial tests a new drug, Kamuvudine-9 (K9), to treat diabetic macular edema (swelling in the back of the eye caused by diabetes). It may help improve vision in people with diabetes who have not yet needed major treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetes (type 1 or 2) and diabetic macular edema (DME) confirmed by your doctor.
- Your vision in the study eye is between 20/50 and 20/320 (moderate to severe vision loss).
- You have not had certain recent eye treatments (like anti-VEGF injections or steroids) or eye surgery.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You weigh at least 55 kg (about 121 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests an investigational drug called SNP318 for people with diabetic macular edema (DME), a condition that causes swelling in the retina and can lead to vision loss. The goal is to see if SNP318 is safe and can improve vision.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.